BERLIN (AP) — Oil and gas company Shell is buying ubitricity, a major provider of electric vehicle charging points in Europe. Shell said Monday that it would buy a 100% stake in the Berlin-based startup, without disclosing the price. Shell said the move represents a further step its “efforts to support drivers as they switch to lower-carbon transport.” The deal, which is subject to regulatory approval, will give Shell ownership of the biggest public EV charging network in Britain with more 2,700 charge points. Ubitricity also has smaller public networks in Germany and France, and has installed over 1,500 charge points for fleet customers across Europe. The company’s focus has been to integrate charge points into existing street infrastructure such as lamp posts.
The C-Band Alliance (CBA) has announced that up to 200 MHz of mid-band spectrum could be cleared to support 5G wireless deployment in the US.In an updated proposal to the US Federal Communications Commission (FCC), the CBA increased the amount of spectrum that could be made available for 5G terrestrial use by 80% compared to the initial proposal made by Intelsat and SES.The CBA – which represents Intelsat, SES, Eutelsat and Telesat – said that the C-band downlink spectrum could be cleared dependent on demand, while protecting current users and critical broadcast services.“The group’s proposal is the only one that balances the needs to protect the C-band user community, which includes television and radio programming distribution to over 100 million US homes, as well as private commercial and government media and data networks with the strong public interest need for rapid 5G network deployment across the US,” said the CBA in a statement.“This announcement allows the CBA and its members to engage in detailed planning of the complicated task of moving customers to different frequency assignments, facilitated through new satellite capacity and innovative technical solutions, implementing new ground infrastructure and modifying the significant existing infrastructure deployed nationwide.”The C-Band Alliance was established by the leading continental US satellite services operators earlier this month to efficiently clear and repurpose C-band spectrum, supporting the US in its 5G deployment and innovation goals.The CBA was developed in response to a proceeding initiated by the US Federal Communications Commission in August 2017.
Reviewed by Kate Anderton, B.Sc. (Editor)Mar 15 2019Less than 10 percent of the treatment recommendations U.S. doctors rely on to manage care for heart patients are based on evidence gained from multiple large, randomized clinical trials — the gold standard for obtaining scientific data.In fact, the proportion of well-supported recommendations for heart care has actually declined compared to 10 years ago, when an earlier analysis found a similar dearth of rigorous studies supporting treatment guidelines. The latest study, led by the Duke Clinical Research Institute, appears online March 15 in JAMA.”In 2009, there was a call for improvement in the clinical research enterprise after that earlier study highlighted several deficiencies,” said senior author Renato Lopes, M.D., Ph.D., a cardiologist and professor of medicine at Duke.”But really, despite some initiatives and a greater focus on conducting randomized controlled trials, the chasm between evidence and the need for evidence has not improved,” Lopes said.”As a matter of fact, the proportion of U.S. recommendations from cardiovascular guidelines supported by high quality evidence actually decreased from 11 percent to 9 percent in the last decade,” Lopes said. “To deliver the health care that our patients deserve, clinical research must be transformed.”Lopes and colleagues, including former FDA commissioner Robert M. Califf, M.D., examined the evidence supporting more than 6,300 treatment recommendations issued by the American College of Cardiology and the American Heart Association (ACC/AHA), and the European Society of Cardiology (ESC).These treatment standards are used to define and manage such basic cardiovascular conditions as high blood pressure and high cholesterol, and adherence is widely considered to improve patients’ outcomes.Related StoriesRNA-binding protein SRSF3 appears to be key factor for proper heart contraction, survivalTeam approach to care increases likelihood of surviving refractory cardiogenic shockCancer incidence among children and young adults with congenital heart diseaseThe quality of the data that buttress the recommendations are important to minimize any inherent study biases and confounding factors, which could then affect real patients in real-world circumstances.Guideline writing committees categorize recommendations by the level of evidence supporting them: Level As are based on evidence gained from multiple randomized control trials; Level Bs are supported by a single randomized control trial or non-randomized studies such as observational analyses; and Level Cs are set by expert opinion. The researchers recorded the level of evidence assigned by guideline writing committees in current guideline documents.According to their review, the Duke-led team found that just 8.5 percent of ACC/AHA recommendations relied on Level A evidence, while 50 percent of studies had Level B data and 41.5 had Level C.”Patients should have an expectation that the science behind the care they receive is solid and will result in improved outcomes,” said lead author Alexander Fanaroff, M.D. “Progress in reducing cardiovascular mortality has decelerated over the past several years, so improving the evidence base for treatment guidelines could help forestall this trend.”Califf noted that technology has advanced greatly in the past decade, and more should be done to incorporate the growing ability to capture data and improve clinical research.”Changes in computing and the widespread use of electronic health records have taken away the technical limitations to a much more efficient and scalable clinical research system,” Califf said. “We need to make the changes in the way the system works so that patients and clinicians can have assurance that their decisions are based on high quality evidence.”Source: https://corporate.dukehealth.org/news-listing/few-treatment-guidelines-heart-disease-are-based-rigorous-study